Last reviewed · How we verify
MK-0476, montelukast sodium
At a glance
| Generic name | MK-0476, montelukast sodium |
|---|---|
| Sponsor | Organon and Co |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysplasia (PHASE1, PHASE2)
- ACTIV-6: COVID-19 Study of Repurposed Medications (PHASE3)
- The Effect of Omalizumab on Allergic Rhinitis Symptoms: a Comparative Study (PHASE4)
- ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast) (PHASE3)
- To Evaluate the Efficacy and Safety of TQC3564 Tablets in the Treatment of Persistent Allergic Rhinitis (PHASE1)
- First Step With Singulair® Therapy (0476-323) (PHASE4)
- To Evaluate the Inflammatory Markers in Adult Patients With Asthma Associated With Allergic Rhinitis Receiving Montelukast Therapy (0476-366) (PHASE3)
- MK0476 Study in Adult Patients With Allergic Rhinitis (0476-378) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK-0476, montelukast sodium CI brief — competitive landscape report
- MK-0476, montelukast sodium updates RSS · CI watch RSS
- Organon and Co portfolio CI